行情

SRPT

SRPT

Sarepta
NASDAQ

实时行情|Nasdaq Last Sale

132.05
+31.58
+31.43%
盘后: 131.60 -0.45 -0.34% 19:59 12/13 EST
开盘
125.50
昨收
100.47
最高
138.79
最低
125.50
成交量
1,079.37万
成交额
--
52周最高
158.80
52周最低
72.05
市值
98.43亿
市盈率(TTM)
-15.4237
分时
5日
1月
3月
1年
5年

分析师评级

24位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

SRPT 新闻

  • Once Shunned For Marketing Approval, Golodirsen Is Now A Major Win For Sarepta
  • Seeking Alpha - Article.1天前
  • UPDATE 2-Sarepta shares surge after surprise approval of Duchenne Muscular Dystrophy drug
  • Reuters.2天前
  • In surprise decision, US approves muscular dystrophy drug
  • The Associated Press.2天前
  • Wave Life Sciences' Suvodirsen May Be Much Better Than Sarepta's Commercialized Eteplirsen, But May Fall Short Of Sarepta's Newer Generation SRP-5051
  • Seeking Alpha - Article.2天前

更多

所属板块

生物技术和医学研究
+1.07%
制药与医学研究
-0.32%

热门股票

名称
价格
涨跌幅

SRPT 简况

Sarepta Therapeutics, Inc. is a biopharmaceutical company. The Company focuses on the discovery and development of ribose nucleic acid (RNA)-targeted therapeutics for the treatment of rare neuromuscular diseases. It operates through discovering, developing, manufacturing and delivering therapies to patients with Duchenne muscular dystrophy (DMD). It is focused on the development of its disease-modifying DMD drug candidates. It has received accelerated approval for its product, EXONDYS 51, indicated for the treatment of DMD in patients who have a confirmed mutation of the DMD gene that is amenable to exon 51 skipping. EXONDYS 51 is studied in clinical trials under the name of eteplirsen. Its next generation phosphorodiamidate morpholino oligomer (PMO)-based compounds are synthetic compounds that bind to complementary sequences of RNA by standard Watson-Crick nucleobase pairing. Its PMO-based chemistries are peptide conjugated PMO (PPMO), PMO-X and PMOplus.
展开

Webull提供Sarepta Therapeutics Inc的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。